Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca plc : AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2013 | 02:26pm CET

AstraZeneca and Bristol-Myers Squibb today announced they have resubmitted to the U.S. Food and Drug Administration (FDA), a New Drug Application (NDA) for dapagliflozin for the treatment of adults with type 2 diabetes.

The NDA resubmission, which is pending acceptance by the FDA, includes several new studies and additional long-term data (up to four years' duration) from previously submitted studies.

NOTES TO EDITORS About dapagliflozin

Dapagliflozin, an investigational compound, is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin. It is currently approved for the treatment of type 2 diabetes in the European Union, Australia, Brazil, Mexico and New Zealand.

About Type 2 Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90 to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterised by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.www.astrazeneca.com

CONTACTS Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)
Vanessa Rhodes +44 20 7604 8037 (UK/Global)
Ayesha Bharmal +44 20 7604 8034 (UK/Global)
Michele Meixell +1 302 885 2677 (US)
Jacob Lund +46 8 553 260 20 (Sweden)

Colleen Proctor + 44 207 604 8128 mob: +1 302 357 4882
Ed Seage + 44 207 604 8125 mob: +1 302 373 1361

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/21ASTRAZENECA : It's OK to use nasal spray flu vaccine again, US panel says
AQ
02/21ASTRAZENECA : U.S. health officials reverse stance on AstraZeneca's flu vaccine
RE
02/21ASTRAZENECA : Announces Renewed Recommendation and Availability of FLUMIST QUADR..
BU
02/21ASTRAZENECA : US panel says it's OK to use nasal spray flu vaccine again
AQ
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
AQ
02/19ASTRAZENECA : European indices gain tracking Asian equities
AQ
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
02/19ASTRAZENECA : FDA grants EAP designation to Guardant's NGS-based liquid biopsy
AQ
02/19ASTRAZENECA : US FDA approves Imfinzi for unresectable Stage III non-small cell ..
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
More news
News from SeekingAlpha
02/21CDC on board with AstraZeneca's Quadrivalent flu vaccine for next year 
02/21YOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
02/20Ionis out-licenses kidney disease candidate to AstraZeneca for up to $330M 
02/19AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In 
02/18BioSci Rounds Report For Feb. 16, 2018 
Financials ($)
Sales 2018 22 326 M
EBIT 2018 5 645 M
Net income 2018 2 145 M
Debt 2018 14 000 M
Yield 2018 4,16%
P/E ratio 2018 33,05
P/E ratio 2019 26,18
EV / Sales 2018 4,38x
EV / Sales 2019 4,12x
Capitalization 83 737 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,8 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-7.96%83 737
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359